Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 97540

Next Previous
Drug Profile

CC 97540

Alternative Names: BMS-986353; CC-97540; CD19-NEX-T; NEX T CD19 - Bristol-Myers Squibb; NEX-T-CD19

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Developer Bristol-Myers Squibb; Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders; Multiple sclerosis; Systemic lupus erythematosus
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 11 Jun 2025 Juno Therapeutics plans a phase II trial for Systemic lupus erythematous and Lupus nephritis (Treatment experienced, In adolescents, In adults, In elderly) in the US, Argentina, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Portugal, Spain and United Kingdom (Parenteral) (EUCT2024-519278-37, NCT07015983), in July 2025
  • 28 May 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in Canada (IV, Injection)
  • 28 May 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in USA (IV, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top